AIM ImmunoTech Inc (AIM) FinancialsAIMAIM ImmunoTech Inc

Evaluating the bottom line, AIM ImmunoTech Inc maintains a gross margin of 80.77%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -13511.54%, while the net margin is -14569.23%. These profitability ratios, combined with a Return on Equity (ROE) of -2382.30%, provide a clear picture of how effectively AIM converts its operational activities into shareholder value.

In the context of the broader market, AIM competes directly with industry leaders such as APRE and BGMS. With a market capitalization of $6.32M, it holds a significant position in the sector. When comparing efficiency, AIM's gross margin of 80.77% stands against APRE's N/A and BGMS's 23.51%. Such benchmarking helps identify whether AIM ImmunoTech Inc is trading at a premium or discount relative to its financial performance.

AIM ImmunoTech has experienced significant revenue fluctuations, with total revenue for 2026/Q2 at $26,000 and a gross margin of 80.77%. Despite losses, the company is making strides in clinical research, particularly with Ampligen, which has shown promising results in trials.